COVID-19: A need for new rather than repurposed antiviral drugs.
D. Kovacs, C. Davis, P. Cannon, M. McFarlane, S. M. Rainey, R. Pinto, M. E. Stewart, A. M. Szemiel, A. Taggart, A. Kohl, F. Marra, E. C. Thomson, J. T. Scott
This paper reviews 29 FDA-approved antiviral compounds for COVID-19 treatment, finds limited clinical efficacy of repurposed drugs, and highlights the need for novel antivirals.
bioRxiv · Mar 25, 2021 · PreprintMicrobiology